The Promise of Tumor Mutational Burden for Cancer Immunotherapy
Quantitative Biomarkers Could Be the Next Step for Precision Oncology
Just Enough Downstream Innovation
Downstream Operations Can Relieve the Pressure of Higher Titers and Cell Densities without Undue Disruption
Snag-Free Combing of the Proteome
With the Right Conditioning Raw Samples May Become More Manageable
Love, Science, and Autoimmune Therapy
NYU Professor Advances Autoimmune Disease Therapeutics
For full access to this article login to GEN Select now.
Capitalizing on miRNA Research
- Aberrant expression of microRNA (miRNA) in human cancers is a common phenomenon. miRNAs regulate many tumor suppressor genes and oncogenes, therefore acting as oncogenes or tumor suppressor genes themselves to directly regulate cancer cell survival and proliferation. In tumor cells, inhibiting miRNAs that are overexpressed, and restoring intracellular ...
Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.
Get GEN Select Access Now
- Do not put any letters or characters here if you are not a spy program.